VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
UTHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
UTHRUnited Therapeutics Corporation
$584.10$24.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. UTHR
  4. Financial Ratios

United Therapeutics Corporation (UTHR) Financial Ratios

Latest Ratios: P/E Ratio 21.5x · EV/EBITDA 16.4x · ROE 19.7%. (1998–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

UTHR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$24.8B$23.3B$17.1B$10.9B$13.5B$10.2B$6.8B$3.9B$4.8B$6.6B$6.7B
Enterprise Value$23.3B$21.8B$15.7B$10.4B$13.3B$10.1B$6.8B$4.0B$4.4B$6.2B$5.7B
P/E Ratio →21.5017.4914.3211.1018.5421.4813.15—8.1315.899.41
P/S Ratio7.787.335.954.706.976.064.562.662.943.854.20
P/B Ratio3.943.292.661.832.812.581.991.391.723.163.60
P/FCF28.5922.4315.8414.6220.3221.419.72—8.0717.1311.18
P/OCF15.8814.9512.8911.1716.8117.098.96—6.1614.0110.43

P/E links to full P/E history page with 30-year chart

UTHR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—6.865.464.486.886.014.612.742.693.593.56
EV / EBITDA16.4113.6110.848.4212.9316.7110.62—5.207.325.20
EV / EBIT15.3412.599.937.8113.4714.7411.45—5.456.055.37
EV / FCF—20.9714.5413.9420.0821.219.81—7.3615.959.48

UTHR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin87.9%87.9%89.2%88.9%92.4%92.7%92.7%91.9%87.8%93.9%95.5%
Operating Margin47.7%47.7%47.9%50.9%50.6%33.0%40.0%-12.9%49.5%47.2%66.4%
Net Profit Margin41.9%41.9%41.5%42.3%37.6%28.2%34.7%-7.2%36.2%24.2%44.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE19.7%19.7%19.2%18.3%16.6%12.9%16.7%-3.8%24.1%21.1%41.2%
ROA17.5%17.5%16.4%14.9%13.0%9.7%12.1%-2.9%18.8%16.1%31.6%
ROIC21.4%21.4%19.6%17.6%17.3%11.4%14.0%-5.3%30.1%49.2%98.8%
ROCE21.8%21.8%21.2%19.6%18.5%12.1%15.3%-5.7%29.0%36.8%56.8%

UTHR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.010.010.050.120.170.200.240.310.090.12—
Debt / EBITDA0.020.020.210.570.781.321.24—0.300.30—
Net Debt / Equity—-0.21-0.22-0.08-0.03-0.020.020.04-0.15-0.22-0.55
Net Debt / EBITDA-0.95-0.95-0.96-0.41-0.16-0.160.10—-0.50-0.54-0.94
Debt / FCF—-1.46-1.29-0.68-0.24-0.200.09—-0.71-1.17-1.70
Interest Coverage88.8988.8936.8722.4930.5236.9325.38-2.7357.73113.60271.59

Net cash position: cash ($1.6B) exceeds total debt ($38M)

UTHR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio6.606.605.254.419.857.616.704.036.393.264.29
Quick Ratio6.286.285.034.289.557.306.443.836.033.013.98
Cash Ratio2.782.784.433.728.276.325.683.215.122.093.16
Asset Turnover—0.400.390.320.320.330.320.370.480.600.69
Inventory Turnover2.102.101.962.301.441.311.251.261.970.980.73
Days Sales Outstanding—40.1635.4343.7441.5543.0338.7338.1439.4062.8548.97

UTHR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield4.7%5.7%7.0%9.0%5.4%4.7%7.6%—12.3%6.3%10.6%
FCF Yield3.5%4.5%6.3%6.8%4.9%4.7%10.3%—12.4%5.8%8.9%
Buyback Yield4.0%4.3%5.9%0.1%0.1%0.1%0.1%0.1%0.0%3.8%7.4%
Total Shareholder Yield4.0%4.3%5.9%0.1%0.1%0.1%0.1%0.1%0.0%3.8%7.4%
Shares Outstanding—$48M$49M$50M$49M$47M$45M$44M$44M$45M$47M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrong
Balance SheetFortress
Cash FlowMixed
Top Statement Risk

Tyvaso generic and Winrevair competition

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Price in Pipeline Optionality

Based on reported figures, UTHR trades at a 20.17 trailing P/E and 13.94 EV/EBITDA, a discount to the 40.48 P/E of Halozyme yet a premium to the 9.27 P/E of ACADIA, while revenue growth has slowed to roughly 4.1 percent year over year.

A trailing P/E of 20.17 paired with a forward P/E of 22.56 implies that consensus expects earnings to contract over the next period, which is inconsistent with a simple growth multiple and suggests the valuation leans on sustained margins rather than expansion. The PEG of 1.05 appears reasonable only if one accepts the pipeline contribution as durable, since reported top-line growth has decelerated sharply from mid-teens rates. Investors should monitor whether the 3.79 price-to-book multiple remains supportable as the asset base grows without commensurate earnings gains.

Margin Compression From Peak Levels

According to reported quarterly figures, UTHR's operating margin fell from roughly 48.7 percent in 2025Q3 to 37.0 percent in 2026Q3, while gross margin held near 88 percent, indicating the decline originates below the gross line.

Because gross margin has remained stable in the high-80s, the compression in operating margin likely reflects rising R&D and operating expense rather than pricing or cost-of-goods pressure in the core franchise. This pattern suggests net margin of 31.1 percent in the latest quarter may understate underlying franchise economics if pipeline spending is discretionary, though that interpretation depends on whether the spend yields future revenue. Operating margin is the more informative measure of current earning power here, since net margin is volatile with interest and other income.

Returns Eroding Despite Strong Franchise

As reported in financial statements, UTHR's ROIC declined to 4.8 percent in 2026Q3 from 5.7 percent in 2025Q1, while ROE of 4.1 percent sits well below the 180.6 percent reported for Halozyme, reflecting a large equity base relative to earnings.

The low ROIC and ROE appear driven by a substantial cash and equity base accumulating against modest after-tax earnings, rather than by weak operating economics, given the high gross margin. The trend suggests capital is compounding more slowly as earnings have declined, a dynamic that may indicate diminishing returns on recent capital deployment including acquisitions. Investors should distinguish between the structural capital intensity of the business and the cyclical drag from elevated pipeline spending.

Ample Liquidity With a Narrowing Cash Buffer

According to reported figures, UTHR's current ratio stands at 4.61 and quick ratio at 4.29 in 2026Q3, yet cash declined from $1.8B to $1.2B in a single quarter, which may indicate a thinner near-term buffer than headline ratios imply.

The very high current and quick ratios, with inventory days near 36, suggest the liquidity position is not dependent on inventory conversion, which is favorable under stress. However, the rapid drawdown in cash alongside rising acquisition outflows warrants investigation into whether capital deployment is outpacing operating cash generation. Under a severe stress scenario, the near-zero debt position provides meaningful flexibility, though the pace of cash consumption deserves continued scrutiny.

Misapplied Current Ratio Obscures Cash Trend

Based on reported figures, the current ratio of 4.61 is most commonly cited as evidence of financial strength, but it can mask the quarterly cash decline and the concentration of current assets in receivables and cash that do not reflect franchise durability.

For a recurring-therapy business with minimal inventory and no meaningful debt, the current ratio primarily reflects the level of retained cash and receivables rather than operating resilience, and it can overstate strength when liquidity is being deployed into acquisitions. A more informative alternative is free cash flow coverage of fixed commitments combined with a trend analysis of cash balances, which better captures whether the buffer is being maintained. Investors should treat the high current ratio as a necessary but insufficient indicator of financial health.

Download Financial Ratios Data

Includes 30+ ratios · 28 years · Updated daily

Consensus & Technical Research Suite
Open UTHR Terminal

UTHR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

UTHR — Frequently Asked Questions

Quick answers to the most common questions about buying UTHR stock.

What is United Therapeutics Corporation's P/E ratio?

United Therapeutics Corporation's current P/E ratio is 21.5x. The historical average is 31.5x. This places it at the 70th percentile of its historical range.

What is United Therapeutics Corporation's EV/EBITDA?

United Therapeutics Corporation's current EV/EBITDA is 16.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.0x.

What is United Therapeutics Corporation's ROE?

United Therapeutics Corporation's return on equity (ROE) is 19.7%. The historical average is 5.3%.

Is UTHR stock overvalued?

Based on historical data, United Therapeutics Corporation is trading at a P/E of 21.5x. This is at the 70th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are United Therapeutics Corporation's profit margins?

United Therapeutics Corporation has 87.9% gross margin and 47.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does United Therapeutics Corporation have?

United Therapeutics Corporation's Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.